TheraRadar
← Back
Data updated: Jun 28, 2026

CEPHALON

Big Pharma
OncologyImmunologyGastroenterology Execution: Good

CEPHALON is a major pharmaceutical company focused on Oncology, Immunology, Gastroenterology.

1993
Since
6
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

CEPHALON at a Glance

  • Fast trial execution (20 months median completion)

CEPHALON's Key Drugs

CEPHALON's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CEPHALON's Recent FDA Approvals

New NDA/BLA approvals for CEPHALON over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CEPHALON's Therapeutic Areas

CEPHALON's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Immunology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 82%
2 drugs Phase 3: 2 Phase 2: 3 Phase 1: 5
Immunology 16%
0 drugs Phase 3: 1 Phase 2: 1
Gastroenterology 3%
0 drugs Phase 1: 1

CEPHALON's Top Competitors

CEPHALON's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Gastroenterology, Oncology
Pfizer big-pharma
Oncology, Immunology
PF PRISM CV big-pharma
Oncology, Immunology, Gastroenterology

CEPHALON Pipeline Snapshot

CEPHALON has 13 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 4 Phase 2 and 6 Phase 1.

3
Phase 3
4
Phase 2
6
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 6/8 completed
  • • Speed: 20 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges